BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37541098)

  • 1. Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [
    Vogler L; Ballweg A; Bohr B; Briel N; Wind K; Antons M; Kunze LH; Gnörich J; Lindner S; Gildehaus FJ; Baumann K; Bartenstein P; Boening G; Ziegler SI; Levin J; Zwergal A; Höglinger GU; Herms J; Brendel M
    Neuroimage Clin; 2023; 39():103484. PubMed ID: 37541098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo imaging of synaptic density with [
    Xiong M; Roshanbin S; Rokka J; Schlein E; Ingelsson M; Sehlin D; Eriksson J; Syvänen S
    Neuroimage; 2021 Oct; 239():118302. PubMed ID: 34174391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of synthetic PET images of synaptic density and amyloid from
    Wang R; Liu H; Toyonaga T; Shi L; Wu J; Onofrey JA; Tsai YJ; Naganawa M; Ma T; Liu Y; Chen MK; Mecca AP; O'Dell RS; van Dyck CH; Carson RE; Liu C
    Med Phys; 2021 Sep; 48(9):5115-5129. PubMed ID: 34224153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study.
    Brendel M; Probst F; Jaworska A; Overhoff F; Korzhova V; Albert NL; Beck R; Lindner S; Gildehaus FJ; Baumann K; Bartenstein P; Kleinberger G; Haass C; Herms J; Rominger A
    J Nucl Med; 2016 Jun; 57(6):954-60. PubMed ID: 26912428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Ballweg A; Klaus C; Vogler L; Katzdobler S; Wind K; Zatcepin A; Ziegler SI; Secgin B; Eckenweber F; Bohr B; Bernhardt A; Fietzek U; Rauchmann BS; Stoecklein S; Quach S; Beyer L; Scheifele M; Simmet M; Joseph E; Lindner S; Berg I; Koglin N; Mueller A; Stephens AW; Bartenstein P; Tonn JC; Albert NL; Kümpfel T; Kerschensteiner M; Perneczky R; Levin J; Paeger L; Herms J; Brendel M
    J Neuroinflammation; 2023 Mar; 20(1):68. PubMed ID: 36906584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tracing synaptic loss in Alzheimer's brain with SV2A PET-tracer UCB-J.
    Kumar A; Scarpa M; Nordberg A
    Alzheimers Dement; 2024 Apr; 20(4):2589-2605. PubMed ID: 38363009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
    Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
    Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of [
    Chen MK; Mecca AP; Naganawa M; Gallezot JD; Toyonaga T; Mondal J; Finnema SJ; Lin SF; O'Dell RS; McDonald JW; Michalak HR; Vander Wyk B; Nabulsi NB; Huang Y; Arnsten AF; van Dyck CH; Carson RE
    J Cereb Blood Flow Metab; 2021 Sep; 41(9):2395-2409. PubMed ID: 33757318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthy brain aging assessed with [
    Andersen KB; Hansen AK; Knudsen K; Schacht AC; Damholdt MF; Brooks DJ; Borghammer P
    Nucl Med Biol; 2022; 112-113():52-58. PubMed ID: 35820300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [
    Finnema SJ; Toyonaga T; Detyniecki K; Chen MK; Dias M; Wang Q; Lin SF; Naganawa M; Gallezot JD; Lu Y; Nabulsi NB; Huang Y; Spencer DD; Carson RE
    Epilepsia; 2020 Oct; 61(10):2183-2193. PubMed ID: 32944949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [
    Zheng C; Holden D; Zheng MQ; Pracitto R; Wilcox KC; Lindemann M; Felchner Z; Zhang L; Tong J; Fowles K; Finnema SJ; Nabulsi N; Carson RE; Huang Y; Cai Z
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1482-1496. PubMed ID: 34761284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Aβ deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [
    O'Dell RS; Mecca AP; Chen MK; Naganawa M; Toyonaga T; Lu Y; Godek TA; Harris JE; Bartlett HH; Banks ER; Kominek VL; Zhao W; Nabulsi NB; Ropchan J; Ye Y; Vander Wyk BC; Huang Y; Arnsten AFT; Carson RE; van Dyck CH
    Alzheimers Res Ther; 2021 Jan; 13(1):11. PubMed ID: 33402201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.
    Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A
    J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synaptic Damage and Its Clinical Correlates in People With Early Huntington Disease: A PET Study.
    Delva A; Michiels L; Koole M; Van Laere K; Vandenberghe W
    Neurology; 2022 Jan; 98(1):e83-e94. PubMed ID: 34663644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Animal PET Imaging of Tau Pathology with 18F-THK5117 in 2 Transgenic Mouse Models.
    Brendel M; Jaworska A; Probst F; Overhoff F; Korzhova V; Lindner S; Carlsen J; Bartenstein P; Harada R; Kudo Y; Haass C; Van Leuven F; Okamura N; Herms J; Rominger A
    J Nucl Med; 2016 May; 57(5):792-8. PubMed ID: 26912432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation and noninvasive kinetic modeling of [
    Bertoglio D; Verhaeghe J; Miranda A; Kertesz I; Cybulska K; Korat Š; Wyffels L; Stroobants S; Mrzljak L; Dominguez C; Liu L; Skinbjerg M; Munoz-Sanjuan I; Staelens S
    J Cereb Blood Flow Metab; 2020 Jun; 40(6):1351-1362. PubMed ID: 31307287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET.
    Rominger A; Brendel M; Burgold S; Keppler K; Baumann K; Xiong G; Mille E; Gildehaus FJ; Carlsen J; Schlichtiger J; Niedermoser S; Wängler B; Cumming P; Steiner H; Herms J; Haass C; Bartenstein P
    J Nucl Med; 2013 Jul; 54(7):1127-34. PubMed ID: 23729696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of Synaptic Density in Neurodegenerative Disorders.
    Carson RE; Naganawa M; Toyonaga T; Koohsari S; Yang Y; Chen MK; Matuskey D; Finnema SJ
    J Nucl Med; 2022 Jun; 63(Suppl 1):60S-67S. PubMed ID: 35649655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SV2A PET Imaging Is a Noninvasive Marker for the Detection of Spinal Damage in Experimental Models of Spinal Cord Injury.
    Bertoglio D; Halloin N; Lombaerde S; Jankovski A; Verhaeghe J; Nicaise C; Staelens S
    J Nucl Med; 2022 Aug; 63(8):1245-1251. PubMed ID: 35027368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.